



REMARKABLE SCIENCE. ENDURING PERFORMANCE.™

Revance Therapeutics
Investor Relations Department
7555 Gateway Boulevard
Newark, CA 94560
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: RVNC


Last Trade:	31.15
Trade Time:	4:00 PM ET May 25, 2018
Change:	0.40 (+1.301%)
Day Range	30.55 - 31.25
52-Week Range	21.60 - 37.45
Volume	127,757

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis, with plans to initiate studies in upper limb spasticity and chronic migraine. RT002 has the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide t... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 24, 2018 [Revance Announces Publication of Positive 24-Week Duration of Effect Results from Cervical Dystonia Phase 2 Trial in Movement Disorders Clinical Practice](#)
- May 15, 2018 [Revance to Participate in the UBS Global Healthcare Conference](#)
- May 9, 2018 [Revance Therapeutics Announces Two Recent Additions to Its Management Team](#)
- May 8, 2018 [Revance Releases First Quarter 2018 Results](#)
- May 1, 2018 [Revance Therapeutics Expands Leadership Team, Appointing Caryn McDowell as SVP, General Counsel & Corporate Secretary](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Mar 2, 2018 [Annual Report \(10-K\)](#)
- Mar 20, 2018 [Proxy Statement \(DEF 14A\)](#)
- May 9, 2018 [Quarterly Report \(10-Q\)](#)
- Nov 3, 2017 [Quarterly Report \(10-Q\)](#)
- Aug 4, 2017 [Quarterly Report \(10-Q\)](#)